Strattice Mesh Lawsuit: Allegations, Bellwether Verdict, and Settlements

The Strattice mesh lawsuits are hundreds of product liability cases filed against LifeCell Corporation, Allergan, and AbbVie’s Allergan Aesthetics division by patients who say the porcine hernia mesh degraded inside their bodies, causing their hernias to return and forcing follow-up surgery. The cases are consolidated as a Multi-County Litigation in New Jersey state court, with a parallel federal consolidation in the District of New Jersey. The first bellwether trial ended in a defense verdict on March 22, 2024, and the plaintiffs’ counsel announced an appeal.¹

Who Is Being Sued

The named defendants are LifeCell Corporation, Allergan, Inc., and Allergan USA, Inc.²³⁴

Strattice Reconstructive Tissue Matrix is a biologic mesh made from porcine acellular dermal matrix. It is sold for reinforcing or repairing soft tissue, including hernia defects and body wall reconstruction, and is marketed as an alternative to synthetic meshes made from polypropylene or polyester.⁴

What Plaintiffs Say Went Wrong

The core allegation is that Strattice breaks down inside the body instead of providing the durable tissue support it was marketed to deliver. When the mesh degrades, plaintiffs say, the original hernia returns, often requiring a second operation to remove the Strattice and replace it with a different product.⁵ Other injuries reported in the complaints include chronic pain, nerve damage, abscesses, infections, organ puncture, and internal bleeding.⁶

The legal theories raised across the consolidated cases include:

Design defect, on the theory that Strattice is unreasonably dangerous, particularly for obese and other vulnerable patients.
Failure to warn patients and their surgeons about the risk of mesh degradation and hernia recurrence.
Fraud and misleading marketing, alleging the manufacturers misrepresented the product’s safety profile and concealed unfavorable information.
Breach of warranty and negligence tied to the product’s alleged failure to perform as represented.
Punitive damages, on the argument that the manufacturers acted with knowledge or reckless disregard for patient safety.

Where the Cases Are Filed

In October 2021, the Strattice cases were designated as a Multi-County Litigation in the Superior Court of New Jersey, Atlantic County, under the caption In Re Strattice Hernia Mesh Litigation, Master Case No. ATL-L-3857-21.⁷ Judge John C. Porto oversees the consolidated proceedings. A parallel consolidated litigation is pending in the U.S. District Court for the District of New Jersey.⁶

Pretrial Rulings That Shaped the Litigation

In November 2023, Judge Porto granted a plaintiffs’ motion to compel discovery from a related litigation involving AlloDerm, another LifeCell tissue matrix product, this one made from human tissue. The defendants argued the two products were too different to share discovery, but the judge found “substantial similarity” between them. He cited the shared patent, LifeCell’s internal documents describing both products as using the same tissue regeneration mechanism, and a LifeCell employee’s testimony that the processing methods for both are “very similar.”⁸ The ruling gave plaintiffs access to depositions and exhibits from the separate AlloDerm MCL.

Before the first bellwether went to trial, Judge Porto denied the defendants’ motion for summary judgment. He also found that a jury could reasonably conclude the defendants “knowingly withheld or misrepresented information or acted with actual malice,” which allowed the punitive damages claim to reach the jury.⁶

The Blakely Bellwether Verdict

The first case to go to trial was Blakely v. LifeCell Corp., et al., Case No. ATL-L-001214-22. Jury selection began on March 4, 2024. Theresa Blakely had received a Strattice mesh during a hernia repair and was diagnosed with a recurrent ventral hernia roughly a year later. She testified that the failure cost her independence. On June 3, 2021, surgeons removed the Strattice and replaced it with a synthetic Parietex mesh.⁵

During trial, Judge Porto granted a directed verdict for the defense on count two of the complaint, dismissing it with prejudice, and denied all other defense motions for directed verdict. On March 22, 2024, the jury cleared LifeCell of liability. Plaintiffs’ counsel at Cohen and Malad announced plans to appeal.¹

What Is Scheduled Next

In August 2024, Judge Porto issued Case Management Order No. 12, which set the schedule for the defendants’ first trial selection. The order established deadlines for dispositive motions by late 2024, oral arguments in February 2025, and a second trial to begin on April 28, 2025.⁹ The MCL case list was updated as recently as April 2026, and the consolidated litigation remains active.⁷

Have Any Cases Settled

No public settlement has been reported in the Strattice-specific litigation as of mid-2026. With a defense verdict in the first bellwether and the appeal pending, the litigation is in a relatively early posture.

The Clinical Evidence Being Disputed

The clinical record on Strattice is itself part of the fight. A 2013 study of 41 intermediate-risk patients who received Strattice for abdominal wall reconstruction reported a 0% hernia recurrence rate over an average follow-up of about 15 months, with no patients requiring mesh removal. The overall 30-day complication rate was 22%, driven mostly by seromas and wound issues.¹⁰

Other data are less favorable. A 2013 study by Clemens and colleagues found Strattice had a 10.1% intraoperative device failure rate, attributed to tearing or uneven thickness, compared to 0% for SurgiMend, a bovine-derived alternative. The same study reported a 7.2% bulge rate for Strattice at 21-month follow-up. A separate study by Booth and colleagues reported an 18% recurrence rate for Strattice, compared to 5.8% for SurgiMend, in mesh-reinforced repairs.¹¹

A 2023 systematic review and meta-analysis in the journal Surgery challenged the assumption that biologic meshes like Strattice are safer than synthetic meshes in contaminated surgical fields. Analyzing four randomized controlled trials, the authors found that biologic meshes had significantly higher hernia recurrence rates and higher surgical site infection rates than synthetic meshes. The authors also noted that biologic meshes can cost up to 200 times more than synthetic ones, adding an estimated $500 million annually to U.S. healthcare spending.¹² The safety advantage over synthetics has been a central selling point for biologic mesh, and plaintiffs point to this line of evidence in arguing that Strattice does not deliver what was promised.

1
The Indiana Lawyer. LifeCell Not Liable, Jurors Rule in Strattice Mesh Hernia Lawsuit
2
Fight for Victims. Lawyer Requests Multi-County Litigation in Strattice Hernia Mesh Lawsuits
3
PR Newswire. Allergan Successfully Completes LifeCell Acquisition
4
Allergan Aesthetics (AbbVie). About Strattice Reconstructive Tissue Matrix
5
Top Class Actions. Woman Testifies Strattice Surgical Mesh Caused Hernia to Reoccur
6
Cohen and Malad. Strattice Mesh Trial
7
NJ Courts. Strattice Hernia Mesh MCL Case List
8
NJ Courts. Motion to Compel – Strattice Hernia Mesh Litigation
9
NJ Courts. Case Management Order No. 12 – Strattice Hernia Mesh Litigation
10
National Library of Medicine (PMC). Critical Analysis of Strattice Performance in Complex Abdominal Wall Reconstruction
11
Integra LifeSciences. Clinical Evidence Summary – Abdominal Wall Reconstruction
12
Surgery. Biologic Versus Synthetic Mesh in Ventral Hernia Repair – A Systematic Review and Meta-Analysis